Haptoglobin (HP) Genotyping
0040116
Ordering Recommendation
Assess genetic risk for coronary artery disease.
Mnemonic
HAPTO PCR
Methodology
Polymerase Chain Reaction/Fluorescence Monitoring
Performed
Mon, Thu
Reported
2-7 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
  
Collect
Lavender (EDTA), pink (K2EDTA), or yellow (ACD Solution A or B).  
Specimen Preparation
Transport 3 mL whole blood. (Min: 1 mL)  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
  
Remarks
  
Stability
Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable  
Reference Interval
By report  
Interpretive Data
Interpretive Data:
Background Information for Haptoglobin (HP) Genotyping:
Characteristics:
Hp genotype is a predictor of cardiovascular disease in diabetic patients. There is no known correlation between the Hp genotype and cardiovascular risk in nondiabetics. Diabetics with the Hp 2-2 genotype are five times more likely to have cardiovascular disease than those with the Hp 1-1 genotype and may benefit from vitamin E treatment. Diabetics who have the Hp 1-1 genotype are at decreased risk for developing microvascular complications such as nephropathy, retinopathy or for restenosis following percutaneous coronary angioplasty.
Incidence:
The Hp 1 and Hp 2 allele frequencies vary across populations. Asians have the highest frequency of Hp 2. The Hp 2-2 genotype is 36 percent in Northwestern Europeans.
Inheritance:
Autosomal recessive.
Alleles Tested:
Hp 1 and Hp 2.
Clinical Sensitivity:
Unknown.
Methodology:
Polymerase chain reaction and fluorescence monitoring.
Analytical Sensitivity and Specificity:
98 percent.
Limitations:
Diagnostic errors can occur due to rare sequence variations. Anhaptoglobinemia (Hp0-0) or hypohaptoglobinemia (Hp 1-0 or Hp 2-0) may be misclassified depending on the cause of lack of gene expression.

This test is performed pursuant to an agreement with Roche Molecular Systems, Inc.
This test is performed pursuant to an agreement with Synvista, Inc.



Counseling and informed consent are recommended for genetic testing. Consent forms are available online at www.aruplab.com.

See Compliance Statement C: www.aruplab.com/CS  
Note
This test is not recommended for the assessment of cardiovascular risk in nondiabetics as there is poor evidence of a correlation between the genotype and cardiovascular risk.
CPT Code(s)
81479
Components
Component Test Code*Component Chart Name
0040127Haptoglobin (HP) Genotyping
2001313HAPTO PCR Specimen
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • HP genotyping